What Avid Bioservices does

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) specializing in mammalian cell-culture-based protein production for biotech and pharmaceutical innovators. Founded in 1993 as a subsidiary of Peregrine Pharmaceuticals and spun out as an independent public company (NASDAQ: CDMO) in 2018, Avid was acquired in February 2025 by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion take-private transaction and now operates as a privately held Delaware-incorporated company headquartered in Tustin, California.

The company's technology platform centers on single-use bioreactor-based mammalian cell-culture manufacturing with over 20,000 liters of installed bioreactor capacity, transposase-based proprietary cell line development methods, integrated process and analytical development, and FDA-compliant CGMP production. Operations run across two purpose-built Southern California facilities: a roughly 160,000 sq. ft. Tustin campus supporting late-stage clinical and commercial manufacturing (including the 2023-commissioned Myford DS Line 3) and a 78,000 sq. ft. Early Phase Center of Excellence in Costa Mesa opened in February 2026 for early clinical programs. Avid cites a 23-year FDA inspection track record, 10 successful pre-approval/pre-license inspections, 600+ CGMP batches produced, 7 approved commercial products, and a footprint spanning products marketed in 90+ countries.

Avid generates revenue on a fee-for-service, contract-manufacturing basis through direct enterprise sales to emerging biotech companies, large pharmaceutical companies, and early-stage biologics programs. Services span the full development-to-commercial continuum — cell line development, process development, analytical services, IND-enabling activities, tech transfer, PPQ campaigns, and commercial drug substance supply — and are project-priced and quote-based. The go-to-market is event- and relationship-driven: heavy presence at BIO International, DCAT Week, BPI West, and the JP Morgan Healthcare Conference, supplemented by technical webinars, white papers, and direct senior-executive engagement with biotech and pharma decision-makers. The company employs 350+ staff and is explicitly expanding headcount and capacity to meet growing customer demand.

Name

Avid Bioservices

Legal name

Avid Bioservices, Inc.

Website

https://avidbio.com

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

Avid Bioservices is a mammalian cell-culture biologics CDMO providing process development, analytical, and CGMP manufacturing services from early-phase through commercial supply, serving emerging biotech and large pharmaceutical clients from facilities in Tustin and Costa Mesa, California.

Ownership category

akta.pro rank

Product category

Biologics Contract Manufacturing (CDMO)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Process Development & Tech Transfer Services (CDMO) (HLAGABAL)

Keywords

• Biologics contract manufacturing
• Mammalian cell culture
• Biopharmaceutical CDMO services
• CGMP manufacturing
• Process development services

Headquarters

HQ city

Tustin

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Development and Manufacturing Services: Avid generates revenue through fee-for-service contract manufacturing agreements for mammalian cell culture biologics. Services span process development, analytical testing, CGMP manufacturing, and tech transfer. Revenue is project-based with long-term client relationships typically encompassing multiple phases from early development through commercial supply.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels10 records

Core offering

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end mammalian cell-culture manufacturing services for biopharmaceutical clients. Its offerings span process development, analytical services, CGMP clinical and commercial manufacturing, and quality systems, delivered through two specialized California facilities—a 160,000 sq. ft. Tustin campus for late-stage/commercial production and a 78,000 sq. ft. Costa Mesa Early Phase Center of Excellence.

Product overview

Avid Bioservices is a dedicated biologics Contract Development and Manufacturing Organization (CDMO) providing mammalian cell-culture manufacturing services. The company offers a unified portfolio centered on Mammalian Protein Development & Manufacturing as its core product, supplemented by two specialized facilities: the Early Phase Center of Excellence in Costa Mesa (78,000 sq. ft.) for early clinical programs and the Clinical & Commercial Manufacturing campus in Tustin (160,000 sq. ft.) for late-stage and commercial production. The service portfolio encompasses four integrated modules—Process Development, CGMP Manufacturing, Analytical Services, and Quality Systems—that collectively enable end-to-end capabilities from concept to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Mammalian Protein Development & Manufacturing End-to-end CDMO services for mammalian protein production spanning early development through commercial CGMP manufacturing, including process development, analytical services, and quality systems for biotech and pharmaceutical clients.
• Early Phase Center of Excellence 78,000 square foot purpose-built facility in Costa Mesa, California designed to support early clinical programs with integrated cell line development, process development, analytical development, IND-enabling activities, and early formulation development.
• Clinical & Commercial Manufacturing (Tustin Campus) Approximately 160,000 sq. ft. integrated mammalian protein process development and CGMP manufacturing facility supporting late-stage clinical and commercial biologics production with over 20,000L of installed single-use bioreactor capacity.

Quantifiable outcome

• 10 successful pre-approval/pre-license inspections
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• CHO PluscoreStrategic or Co-development Partner · 5 August 2025CHO Plus partnered with Avid Bioservices as scale-up partner for BARDA's BioMaP Consortium project developing high productivity CHO cell lines for filovirus monoclonal antibody production. Avid provides manufacturing scale-up services to support industrial-scale requirements for the BARDA-funded program worth up to $10.4 million over 30 months.
• BARDA BioMaP ConsortiumcoreOthers · 5 August 2025Avid Bioservices serves as scale-up partner within BARDA's Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), supporting domestic manufacturing capacity for medical countermeasures including filovirus monoclonal antibodies.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Samsung Biologics: Samsung Biologics is one of the world's largest mammalian cell culture CDMOs with massive bioreactor capacity (600,000L+). Direct competitor for commercial-scale biologics manufacturing contracts but operates at materially larger scale than Avid.
• Lonza Biologics: Lonza's Biologics division is the global #1 CDMO offering mammalian cell culture manufacturing from early development through commercial supply. Closest direct competitor in scale, scope, and service mix; competes with Avid for both early-phase and commercial programs.
• Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth Biotechnologies is a leading global CDMO offering mammalian and microbial biologics manufacturing. Notably, Avid's new CEO Kenneth Bilenberg was previously COO of Fujifilm Biotechnologies, making this a particularly relevant peer relationship.
• WuXi Biologics: WuXi Biologics is a major global biologics CDMO based in China offering end-to-end mammalian cell culture services. A key direct competitor but increasingly losing US biotech work to Avid and other US-based CDMOs due to BIOSECURE Act and onshoring trends.
• Catalent (Novo Holdings): Catalent is a major global CDMO (now under Novo Holdings) with biologics manufacturing capabilities among other modalities. Overlaps with Avid in mammalian biologics but operates across a much broader service portfolio.
• Thermo Fisher Scientific (Patheon): Thermo Fisher's Pharma Services (including the legacy Patheon and Brammer Bio biologics operations) is a major global CDMO offering mammalian biologics manufacturing. Broad incumbent competing for late-stage and commercial programs at scale.

Direct peers

• AGC Biologics: AGC Biologics is a pure-play mammalian and microbial biologics CDMO with comparable scale to Avid (~20,000L range). Direct competitor for mid-market biotech and pharma biologics manufacturing programs.
• Rentschler Biopharma: Rentschler Biopharma is a privately held, Germany-based CDMO specializing in mammalian cell culture biologics manufacturing. Very comparable in scale, service mix, and target market (mid-market biotech) to Avid.
• KBI Biopharma: KBI Biopharma is a US-based CDMO focused on mammalian cell culture biologics development and manufacturing. Direct competitor particularly for early-phase programs; comparable footprint and customer profile.

Emerging players

• Bionova Scientific: Bionova Scientific is a US-based biologics CDMO focused on mammalian cell culture development and GMP manufacturing for early-phase programs. Emerging peer with similar focus area to Avid's Early Phase Center of Excellence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/avid-bioservices

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avid Bioservices